Effect of Anti-interleukin 5 (IL5) Therapy on Sputum Cells and Cytokines

Catholic University (KU) of Leuven

Status and phase: Completed; Phase 4

Conditions: Asthma

Treatments: Drug: Mepolizumab Injection [Nucala]

Study type: Interventional

Funder types: Other

Identifiers

NCT04412044

s58608

Details and patient eligibility

About

22 asthmatics, in which mepolizumab was to be started, gave permission for inclusion and were followed up prospectively. Clinical and lung functional data, sputum analyses and cytokine measurements were analyzed.

Enrollment: 22 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• FEV1 < 80% in the last 12 months
• use of high dose inhaled corticosteroids (ICS) in combination with other additional medication or continuous use of oral corticosteroids (OCS)
• at least 2 exacerbations in the last 12 months
• at least 300 blood eosinophils/µl once in the last 12 months and at the time of inclusion
• Anti-IL5 treatment prescribed by the physician

Exclusion criteria

• Not completing all visits

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

Asthmatics

Experimental group

Description:

Patients receive anti-IL5 treatment as part of their prescribed routine. Immunological and clinical parameters will be evaluated at the start of the treatment and after 6 months of treatment

Treatment:

Drug: Mepolizumab Injection [Nucala]